PAR-27-015: Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All

PAR-27-015: Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All

The NIH has released a major community-health funding opportunity focused on oral disease prevention and care delivery transformation. The PAR-27-015 NOFO funds a phased UG3/UH3 cooperative agreement in which teams first test feasibility (UG3) and then scale to implementation/evaluation (UH3). The program is built around community-based participatory research (CBPR) and requires direct, cross-sector collaboration across community and healthcare settings.

This opportunity is a concrete fit for organizations and investigators who can combine rigorous population-based intervention design with strong local partnership structures. It is especially relevant if you work in public health, dental or craniofacial research, implementation science, social determinants of oral health, or community governance systems and are ready to submit under NIH process requirements.

Key details at a glance

What this opportunity funds

The NOFO is explicitly targeted at population-level interventions that improve oral health by integrating services, systems, and values across sectors. It is not a standalone clinic improvement grant, and not a basic science pilot for its own sake. The program expects interventions that can work at the community or societal level and that involve community partners as active collaborators.

The initiative explicitly builds an ADAPT consortium model. Funded UG3/UH3 projects should join an infrastructure that includes shared consultation, data planning support, and cross-site collaboration through the SCHARE platform and CEACR-supported guidance. The expectation is not just to run a study but to become part of an active learning system where community engagement methods, data strategy, and implementation lessons scale across projects.

What gets supported:

• population-based interventions for oral-health-related policy, program, or practice transformation;
• partnerships that combine healthcare and non-healthcare sectors;
• projects with clear milestones for feasibility and scale-up;
• data practices that permit useful sharing and cross-site learning;
• demonstration and implementation activities grounded in community governance.

The program explicitly values work that directly addresses social and chronic disease common-risk factors and barriers that influence oral disease burden. Oral health in this framework is linked to broader health and social outcomes, not only clinical treatment. That framing is important: applicants should avoid framing this as a small-scale service project and instead align with systems-level transformation.

A crucial practical point: this NOFO is designed as a phased mechanism. That means your submission should show both what is credible in the early phase and what can reasonably be tested and expanded in the second phase. If your concept depends on large infrastructure that cannot be piloted in two years, reviewers and program staff will likely see execution risk as too high.

Why this matters in 2026 and 2027

The posted dates are important. The call was posted in late April 2026 and has first open date in September 2026. The key annual submission dates listed include October 16 in 2026, 2027, and 2028, with corresponding review and award windows that extend into the following year.

For the Finder’s perspective in 2026/2027:

• You have a real “current cycle” trajectory to monitor.
• The opportunity is not a one-off historical NOFO.
• It has a recurring cycle pattern in the opportunity text, and a clear expiration in November 2028.

That pattern is useful when maintaining a funding pipeline: if you miss the first cycle, the same opportunity class may still reappear in the same series of dates, but submission planning is usually tighter than a clean annual standalone solicitation cycle because review timing and award administration still depend on NIH appropriations and readiness.

Eligibility: who can apply and who should not apply

NIH eligibility language here is broad but structured. The NOFO states these U.S.-based organizations are eligible in their list: Higher Education Institutions, nonprofits (including but not limited to 501(c)(3) entities), small businesses, for-profit entities, local governments (state/county/city/special district), US territories, some federal agencies, independent school districts, faith-based/community organizations, and regional organizations.

Foreign entities and foreign components are not eligible. NIH calls out eRA Commons registration as a required precondition, and SAM.gov plus UEI requirements are treated as hard gates before a submission can be accepted.

From a practical standpoint, this opportunity behaves like an NIH core-operations grant: it is open to a wide range of organizational types, but operationally the following are often the deciding factors:

• Whether the organization has institutional systems to support NIH compliance and eRA/Grants.gov workflows.
• Whether you can document a true community partnership with clear roles and shared responsibilities, not symbolic letters.
• Whether the team can commit to milestone reporting and data-sharing expectations.
• Whether domestic-only eligibility is fully compliant; international applicants are outside scope.

A common strategy is to submit as a lead organization with clear partner organizations formally supporting the project. The NOFO strongly encourages multi-PD/PI structures including both researcher and community partners; those profiles should share effort equivalently and reflect operational responsibility.

Funding level, budget expectations, and what can be charged

The budget cap details in the NOFO are explicit: up to $300,000/year in direct costs for UG3 and up to $650,000/year in direct costs for UH3. The maximum combined project length is 7 years, with a 2-year UG3 and 5-year UH3 phase.

This is not a guaranteed full-award ladder; UG3 transition to UH3 depends on milestone performance and availability of funds. The NOFO frames transition funding as contingent, not automatic, and includes a go/no-go decision process.

In practical budget planning terms:

• Include budget lines that directly support the design of your milestone trajectory.
• Include travel for the required inaugural consortium meeting where appropriate.
• Budget for data infrastructure and analytics as needed, especially if using cloud tools such as SCHARE.
• Include CEACR consultation costs if your work uses them. The NOFO gives a concrete reference value for those consultations (about $6,000 per consult in the text) and expects budget justification for these costs.
• Include partner support commitments through compliant letters of support with clear contribution statements.

Reviewing budget expectations with this in mind helps avoid under-scoping; the biggest applications that fail not because of weak ideas but because the implementation plan has no operational path to meet milestones at the requested scale.

Eligibility and submission requirements that often block applications

Section III and IV details indicate three practical gates:

• Registration gate: SAM, eRA Commons, and related systems must be active before submission. This is frequently the first issue teams encounter.
• Application formatting gate: NIH Application Guide instructions and NIH portal-specific instructions are enforced.
• Submission timing gate: applications due by 5:00 PM local time of the applicant organization; late or corrected late submissions are usually disallowed.

The NOFO requires a standard NIH format with strict SF424(R&R) pathways and module content. Even when you know your science, the packaging can fail if you do not meet structure requirements. This includes:

• separate UG3 and UH3 research strategy sections,
• valid milestone plans,
• appropriate letters of support,
• required resource and data management sections,
• compliance in Human Subjects and related clinical trial forms (if relevant),
• no extraneous materials in appendices.

Paper submissions are not accepted.

What evidence to include in the package

The NOFO is explicit about support materials:

• Letters of support should not be generic. They should define specific responsibilities, collaboration history, and real resource contribution.
• The study timeline and milestone plan need to state concrete, measurable UG3 go/no-go milestones and annual UH3 milestones.
• DMS (data management and sharing) plan must follow NIH structure and limits.
• Non-negotiable page-limit and form instructions from NIH Apply/Research & Related instructions apply.

The cleanest applications are those where all required pieces map directly to reviewer expectations:

• clear population and community definition,
• specific partners and non-healthcare sector roles,
• operational strategy, and
• clear dissemination and sustainment path.

Review criteria and what reviewers actually evaluate

Applications are reviewed through NIH peer review and selected through the usual merit, funding availability, and priority logic. The NOFO includes standard criteria relevant to translational/public health intervention quality:

• significance and expected impact,
• scientific rigor,
• innovation,
• approach and feasibility,
• investigators’ capability,
• environment and partnership capacity.

For applications involving human subjects, reviewers score protections, risk-benefit logic, and data-safety monitoring as applicable. Vertebrate or biohazard instructions also apply where relevant. The NOFO also calls out budget and period of support reasonableness, meaning your budget narrative must align tightly with your milestones.

A key practical takeaway:

• NIH review is often very literal with non-responsive items.
• If milestones, cross-sector partnership, dissemination plan, and scale pathway are missing or vague, teams move from “good idea” to “non-responsive” quickly.

The selection stage after peer review looks at merit, available funds, and relevance to program priorities. So an application can score well but still lose to fit mismatch.

How to prepare a competitive submission

A disciplined preparation sequence that works for this NOFO:

1. Confirm institutional readiness first
   • SAM/eRA/Grants.gov readiness date at least 6+ weeks out.
   • internal signoff for NIH format submission routes.
2. Define consortium fit early
   • define who is the research lead and who is the community lead.
   • define how data, delivery, and decision-making are shared.
3. Write milestone architecture before writing narrative
   • UG3 go/no-go milestones for feasibility and partnership activation.
   • UH3 yearly milestones for enrollment, implementation quality, and outcome capture.
4. Build a realistic budget narrative
   • include costs linked to mandated requirements (travel, data, CEACR consults if used).
   • include match/in-kind logic only when contractually documented.
5. Prepare core documents once and reuse across sections
   • use letters of support to mirror roles in governance, operations, and evaluation.
   • map the same claims in research strategy, environment, and milestone sections.
6. Run a compliance preflight
   • page limits,
   • appendix restrictions,
   • human subjects fields,
   • DMS format compliance,
   • response-time windows and contact details.

This is not a “prototype only” opportunity. It asks for operational maturity by design. The better teams submit materials that are already internally integrated at organizational level before drafting details.

Common mistakes in this NOFO and how to avoid them

1) Treating clinical/technical ideas as non-community interventions

Many teams propose excellent tools or methods but do not show that community-level systems are truly co-designed. The NOFO expects cross-sector partnerships where community organizations are not token collaborators. Define what each partner controls and contributes.

2) Missing responsiveness requirements

The NOFO explicitly calls out non-responsive patterns such as missing UG3/UH3 scope, missing go/no-go milestones, missing cross-sector partnership detail, and missing dissemination strategy. These are not “minor edits”; they can remove your application from review.

3) Inconsistent timeline design

The two-phase model requires phase-specific planning. If your UH3 section simply repeats UG3 text without implementation detail, reviewers may score low on feasibility and transition clarity.

4) Budget not tied to activity

A direct recurring error is a budget that cannot be traced to specific milestone events. For this opportunity, milestones are central to governance. Keep budgets narrative linked to each major phase milestone and justify each major cost class.

5) Weak letters of support

Letters that say “supportive in principle” without defined obligations weaken partnership credibility. State specific operational commitments, responsibilities, and contribution types.

FAQ (practical)

Is this only for clinical trials?

No. Clinical trial status is optional. Projects can be clinical or non-clinical as long as they align with the intervention and the oral health systems focus.

Can organizations submit with mixed lead roles?

Yes. The NOFO encourages multi-PD/PI structures that include both community partner PD/PI(s) and researcher PD/PI(s). In practice, this is most credible when role partitioning is explicit and effort is balanced where applicable.

Is foreign collaboration possible?

Foreign entities are not eligible as applying entities. Non-domestic components of U.S. organizations are also excluded.

Does this guarantee UH3 funding if awarded UG3?

No. Transition is conditional and based on milestone performance and availability of funds.

Can community organizations lead the grant?

Eligibility is broad, including certain community-oriented entities, but the submitted structure must satisfy NIH cooperative agreement and review standards for capacity, governance, and data plans. Strong operations are mandatory regardless of type.

2026-to-2027 strategy for teams starting now

For teams planning around the first announced open window:

• Start registrations immediately and treat the six-week registration timeline as unavoidable.
• Build the UG3/UH3 split from the start, not at the end.
• Prepare the required human subjects and milestone materials first, then polish scientific narrative.
• Align your first draft around reviewer expectations listed in the NOFO and NIH Application Guide before optimizing language.

If your team is currently in discovery phase, the practical target should be to submit a fully compliant UG3 proposal in the first cycle and use transition decisions as a forced implementation checkpoint.

Official links

• Official ADAPT NOFO: https://files.simpler.grants.gov/opportunities/c4e39e95-ac54-466c-8d9a-774c50c6247c/attachments/cd24ea63-fd5c-4264-979f-83ec62a7d3ec/PAR-27-015-Full-Announcement.html
• NIH How to Apply Application Guide: https://grants.nih.gov/grants/how-to-apply-application-guide
• NIH Grants Policy Statement: https://grants.nih.gov/grants/policy/policy